ClinicalTrials.gg
CompletedNCT03445468Updated May 11, 2020

Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents

A Phase 3 interventional study of IL-YANG Quadrivalent Influenza Vaccine and IL-YANG Flu Vaccine Pre-filled Syringe in Influenza, Human, sponsored by Il-Yang Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 3 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-11.

Sponsored by Il-Yang Pharm. Co., Ltd. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
379
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 60 studies in Influenza, Human with a site in Korea, Republic of — 9 open to participants now, 10 under way, 4 of them phase 3. Influenza, Human · Korea, Republic of.

Enrollment
20th of 55
379 · median 274
Started
2017
with 2 others
Phase 3
28 of 60
3 open now
Registered
31st of 60
by date
Lead sponsor
4 of 60
Il-Yang Pharm. Co., Ltd.

Among the 60 studies in Influenza, Human with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2017, is one of 28 in phase 3, and was the 31st registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

9 of the 60 studies in Influenza, Human with a site in Korea, Republic of are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Influenza, Human with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of 'IL-YANG Quadrivalent Seasonal Influenza Vaccine' in healthy Korean children and adolescents.

Read the detailed description

The study is an open-label(Part 1), Single-arm(Part 1), Randomized(Part 2), Double-blind(Part 2), Active comparator(Part 2) Phase III study.

Before initiation of any protocol-specific activities, written informed consent is obtained from each patient and their legally acceptable representatives. Subjects who meet all of the eligibility criteria after screening assessments as specified in the protocol, are randomized into the test group or the comparator group in a ratio of 4 :1 and receive a single dose or two doses of the study vaccine. The investigator perform the efficacy (immunogenicity) and safety assessments throughout the study. Efficacy data are collected at Visit 1 (prior to vaccination) and at the end-of-study visit for efficacy (immunogenicity) assessments, and for safety assessment, subjects and their legally acceptable representatives are instructed to record any treatment-emergent adverse event in Patient Diary cards.

For all randomized subjects, blood sample is obtained prior to vaccination, and the study vaccine 0.5mL is administered. For children aged from 3 years to \<9 years of age who have not previously received influenza vaccine, another dose of the study vaccine is administered 4 to 5 weeks after the first dose. Blood samples are collected 4 to 5 weeks after the last dose of the study drug for the assessment of antibody titer. All subjects are followed for 6 months after the last dose of the study drug for the safety assessments, and Month 6 follow-up visit is the end-of-study visit.

03

Conditions studied

  • Influenza, Human

Browse trials for

Keywords

  • Influenza vaccine
  • Split influenza vaccine
  • Seasonal influenza vaccine
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men or women aged from 3 years to \< 19 years
  • Subjects were born after full term pregnancy (37 weeks)
  • Woman of must have a negative result from Urine Human Chorionic Gonadotropin(HCG) test at the screening visit.
  • Voluntary written was obtained from the subject and the subject's legally acceptable representative (consent of legally acceptable representative was required for subjects younger than 7 years of age)

Exclusion criteria

Exclusion Criteria:

  • Subject with a known serious allergy reaction after influenza vaccination or to any component vaccine including eggs
  • Subject who had received an influenza vaccine within the last 6 months
  • Subject who has, or has a family history of, an immune system disorder including immune deficiency disease
  • Subject with a history of Guillain-Barre syndrome
  • Subject with Down's syndrome or cytogenetic disorders.
  • Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial
  • Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
  • Subject who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the study vaccine
  • Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period.
  • Subject who had received or immune modifying drug within the last 3 months prior to administration of the study vaccine
  • Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study.
  • Subject who had participated in another experimental study within 28 days prior to administration of the study vaccine
  • Subject with other medical or psychological condition who in the investigator's opinion would not be suitable for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
379 participants (actual)

Study arms

  • Experimental
    IL-YANG Quadrivalent Influenza Vaccine

    The vaccine contains both B strain (Yamagata, Victoria)

    Biological: IL-YANG Quadrivalent Influenza Vaccine

  • Active comparator
    IL-YANG Flu Vaccine Pre-filled Syringe

    The vaccine contains the B/Yamagata strain and it was approved for commercial sale by Ministry of Food and Drug Safety.

    Biological: IL-YANG Flu Vaccine Pre-filled Syringe

Interventions

  • BiologicalIL-YANG Quadrivalent Influenza Vaccine

    A single 0.5mL dose administrated as an intramuscular injection.

  • BiologicalIL-YANG Flu Vaccine Pre-filled Syringe

    A single 0.5mL dose administrated as an intramuscular injection.

06

What researchers measure

Primary outcomes

  1. Seroconversion rate against Hemagglutination Inhibition(HI) antibody

    Seroconversion rate(a lower bound of 95 CI) ≥ 40%

    Time frame: Up to Day28(+7) after the last vaccination

  2. Seroprotection rate against Hemagglutination

    Seroprotection rate(a lower bound of 95 CI) ≥ 70%

    Time frame: Up to Day28(+7) after the last vaccination

Secondary outcomes

  1. Geometric Mean Titer(GMT) and Geometric Mean Ratio(GMR)

    GMT and GMR of HI Antibody Titer Before Vaccination and After Vaccination

    Time frame: Up to Day28(+7) after the last vaccination

07

Study locations

1 site
  • The catholic university of Korea, Seoul ST. Marry's Hospital
    Seoul, 06591, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Dec 2017, 3 months.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 3 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Feb 26, 2018
StartActual
Sep 20, 2017
Primary completionActual
Dec 29, 2017
CompletionActual
Aug 30, 2018
Last update
May 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03445468
Responsible party
Sponsor
First posted
Feb 26, 2018
Start date
Sep 20, 2017
Primary completion
Dec 29, 2017
Completion
Aug 30, 2018
Last update
May 11, 2020

Study contacts

Jin-Han Kang, MD.PhD
principal investigator · The catholic university of Korea, Seoul ST. Marry's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion